Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.

We present a multiplexed and internally calibrated quantitative reverse transcription-PCR (QRT-PCR) assay to detect human glandular kallikrein 2 (hK2) and prostate-specific antigen (PSA) transcripts in blood samples from healthy subjects and prostate cancer (PC) patients. The assay detected 50 copie...

Bibliografske podrobnosti
Main Authors:	Ylikoski, A, Karp, M, Pettersson, K, Lilja, H, Lövgren, T
Format:	Journal article
Jezik:	English
Izdano:	2001

Podobne knjige/članki

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
od: Ylikoski, A, et al.
Izdano: (2002)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
od: Becker, C, et al.
Izdano: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
od: Becker, C, et al.
Izdano: (2003)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
od: Steuber, T, et al.
Izdano: (2005)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
od: Olsson, A, et al.
Izdano: (2004)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
od: Siivola, P, et al.
Izdano: (2000)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
od: Cao, Y, et al.
Izdano: (2002)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
od: Becker, C, et al.
Izdano: (2000)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
od: Olsson, A, et al.
Izdano: (2005)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
od: Väisänen, V, et al.
Izdano: (2006)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
od: Haese, A, et al.
Izdano: (2003)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
od: Becker, C, et al.
Izdano: (2001)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
od: Becker, C, et al.
Izdano: (2000)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
od: Becker, C, et al.
Izdano: (2000)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
od: Haese, A, et al.
Izdano: (2005)

Standardization of two immunoassays for human glandular kallikrein 2.
od: Haese, A, et al.
Izdano: (2003)

Development of sensitive immunoassays for free and total human glandular kallikrein 2.
od: Väisänen, V, et al.
Izdano: (2004)

Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step.
od: Niemelä, P, et al.
Izdano: (2002)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
od: Steuber, T, et al.
Izdano: (2007)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
od: Janssen, S, et al.
Izdano: (2004)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
od: Haese, A, et al.
Izdano: (2001)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
od: Björk, T, et al.
Izdano: (2001)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
od: Haese, A, et al.
Izdano: (2000)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
od: Ulmert, D, et al.
Izdano: (2009)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
od: Steuber, T, et al.
Izdano: (2006)

The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin.
od: Olsson, A, et al.
Izdano: (2004)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
od: Wenske, S, et al.
Izdano: (2009)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
od: Bruun, L, et al.
Izdano: (2004)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
od: Christensson, A, et al.
Izdano: (2011)

Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing.
od: Piironen, T, et al.
Izdano: (2001)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
od: Gupta, A, et al.
Izdano: (2010)

Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes.
od: Ylikoski, A, et al.
Izdano: (2001)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
od: Vickers, A, et al.
Izdano: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
od: Vickers, A, et al.
Izdano: (2008)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
od: Vickers, A, et al.
Izdano: (2010)

Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer
od: Gelareh Vahabzadeh, et al.
Izdano: (2025-01-01)

Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
od: Marilesia Ferreira de Souza, et al.
Izdano: (2017-01-01)

Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood.
od: Rissanen, M, et al.
Izdano: (2007)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
od: Scardino Peter T, et al.
Izdano: (2008-07-01)

Dual-Label Detection of Amplified Products in Quantitative RT-PCR Assay Using Lanthanide-Labeled Probes
od: Alice Ylikoski, et al.
Izdano: (2001-04-01)